JP2019521154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521154A5 JP2019521154A5 JP2019501917A JP2019501917A JP2019521154A5 JP 2019521154 A5 JP2019521154 A5 JP 2019521154A5 JP 2019501917 A JP2019501917 A JP 2019501917A JP 2019501917 A JP2019501917 A JP 2019501917A JP 2019521154 A5 JP2019521154 A5 JP 2019521154A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- tumor
- dna molecule
- cell clone
- transformed cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 41
- 102000036639 antigens Human genes 0.000 claims 40
- 108091007433 antigens Proteins 0.000 claims 40
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 108020004414 DNA Proteins 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 16
- 102000053602 DNA Human genes 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 10
- 108010041986 DNA Vaccines Proteins 0.000 claims 6
- 229940021995 DNA vaccine Drugs 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 241000607142 Salmonella Species 0.000 claims 4
- 230000001580 bacterial effect Effects 0.000 claims 4
- 238000002619 cancer immunotherapy Methods 0.000 claims 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 3
- 229920001817 Agar Polymers 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 239000008272 agar Substances 0.000 claims 2
- 239000000356 contaminant Substances 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000002538 fungal effect Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- ZPLCXHWYPWVJDL-UHFFFAOYSA-N 4-[(4-hydroxyphenyl)methyl]-1,3-oxazolidin-2-one Chemical compound C1=CC(O)=CC=C1CC1NC(=O)OC1 ZPLCXHWYPWVJDL-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241001467018 Typhis Species 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000006285 cell suspension Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022074854A JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16001550.9 | 2016-07-13 | ||
| EP16001550 | 2016-07-13 | ||
| PCT/EP2017/067590 WO2018011289A1 (en) | 2016-07-13 | 2017-07-12 | Process for the production of a dna vaccine for cancer immunotherapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074854A Division JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019521154A JP2019521154A (ja) | 2019-07-25 |
| JP2019521154A5 true JP2019521154A5 (cg-RX-API-DMAC7.html) | 2020-08-20 |
| JP7098599B2 JP7098599B2 (ja) | 2022-07-11 |
Family
ID=56418345
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501917A Active JP7098599B2 (ja) | 2016-07-13 | 2017-07-12 | 癌免疫療法用のｄｎａワクチンの製造方法 |
| JP2022074854A Pending JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022074854A Pending JP2022097591A (ja) | 2016-07-13 | 2022-04-28 | 癌免疫療法用のｄｎａワクチンの製造方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10821163B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3484503A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7098599B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190027834A (cg-RX-API-DMAC7.html) |
| CN (1) | CN109475614A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017295004B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019000657A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3028549A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL263568A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2019000415A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2019100079A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201811258UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018011289A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3050833A1 (en) | 2017-02-17 | 2018-08-23 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
| AU2019301699C1 (en) | 2018-07-11 | 2024-10-10 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| AU2019334131B2 (en) | 2018-09-05 | 2025-12-18 | NEC Oncolmmunity AS | Neoantigen targeting DNA vaccine for combination therapy |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| WO2021144254A1 (en) | 2020-01-13 | 2021-07-22 | Vaximm Ag | Salmonella-based dna vaccines in combination with an antibiotic |
| JPWO2024005122A1 (cg-RX-API-DMAC7.html) * | 2022-06-30 | 2024-01-04 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT4223311T (pt) * | 2011-05-24 | 2025-08-21 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Vacinas individualizadas para o cancro |
| MX355134B (es) * | 2011-12-22 | 2018-04-06 | Vaximm Ag | Metodo para producir cepas atenuadas de salmonella con alto rendimiento. |
| US9415098B2 (en) * | 2012-07-05 | 2016-08-16 | Vaximm Ag | DNA vaccine for use in pancreatic cancer patients |
| JP6416877B2 (ja) * | 2013-04-25 | 2018-10-31 | バクシム アクチェンゲゼルシャフト | ウィルムス腫瘍遺伝子ｗｔ１を標的とする癌免疫療法用のサルモネラベースのベクター |
| JP6662787B2 (ja) * | 2013-12-18 | 2020-03-11 | バキシム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌免疫療法のための新規ｍｓｌｎ標的化ｄｎａワクチン |
| NZ721908A (en) * | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
-
2017
- 2017-07-12 KR KR1020197002050A patent/KR20190027834A/ko not_active Ceased
- 2017-07-12 CN CN201780043297.1A patent/CN109475614A/zh active Pending
- 2017-07-12 CA CA3028549A patent/CA3028549A1/en active Pending
- 2017-07-12 BR BR112019000657-5A patent/BR112019000657A2/pt not_active Application Discontinuation
- 2017-07-12 JP JP2019501917A patent/JP7098599B2/ja active Active
- 2017-07-12 EP EP17743277.0A patent/EP3484503A1/en active Pending
- 2017-07-12 US US16/315,606 patent/US10821163B2/en active Active
- 2017-07-12 WO PCT/EP2017/067590 patent/WO2018011289A1/en not_active Ceased
- 2017-07-12 MX MX2019000415A patent/MX2019000415A/es unknown
- 2017-07-12 RU RU2019100079A patent/RU2019100079A/ru not_active Application Discontinuation
- 2017-07-12 KR KR1020237018125A patent/KR20230079514A/ko not_active Ceased
- 2017-07-12 SG SG11201811258UA patent/SG11201811258UA/en unknown
- 2017-07-12 AU AU2017295004A patent/AU2017295004B2/en active Active
-
2018
- 2018-12-06 IL IL263568A patent/IL263568A/en unknown
-
2020
- 2020-09-29 US US17/037,627 patent/US11590215B2/en active Active
-
2022
- 2022-04-28 JP JP2022074854A patent/JP2022097591A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521154A5 (cg-RX-API-DMAC7.html) | ||
| RU2019100079A (ru) | Способ получения днк-вакцины для иммунотерапии рака | |
| IL299249B1 (en) | Genetically modified immune cells that include adapted shrna-microRNA (shrnamir) | |
| CN113711239A (zh) | 利用ii类mhc模型鉴别新抗原 | |
| RU2016136855A (ru) | Биомаркер-направленная многоцелевая иммунотерапия | |
| Bolinger et al. | Adenoviral vector vaccination induces a conserved program of CD8+ T cell memory differentiation in mouse and man | |
| Fredericks et al. | The species-specific acquisition and diversification of a K1-like family of killer toxins in budding yeasts of the Saccharomycotina | |
| CN111868080A (zh) | 利用泛等位基因模型进行的新抗原鉴别 | |
| JP2019510465A5 (cg-RX-API-DMAC7.html) | ||
| JP2018511321A5 (cg-RX-API-DMAC7.html) | ||
| CN104560864A (zh) | 利用CRISPR-Cas9系统构建的敲除IFN-β基因的293T细胞系 | |
| CN105331635A (zh) | 一种诱导型慢病毒表达体系及其构建方法和应用 | |
| Malouli et al. | Cytomegalovirus-vaccine-induced unconventional T cell priming and control of SIV replication is conserved between primate species | |
| WO2020124830A1 (zh) | 基于人工串联启动子的枯草芽孢杆菌高效诱导表达系统 | |
| JP2019511218A5 (cg-RX-API-DMAC7.html) | ||
| CN105132350B (zh) | 一种减毒鼠伤寒沙门氏菌的构建方法及其所得菌株和应用 | |
| CN103739682A (zh) | 一种针对宫颈癌具有免疫原性的蛋白及其应用 | |
| Pfenninger et al. | Naïve primary mouse CD8+ T cells retain in vivo immune responsiveness after electroporation-based CRISPR/Cas9 genetic engineering | |
| Kistler et al. | Structural dynamics of Fusarium genomes | |
| JP2015507472A5 (cg-RX-API-DMAC7.html) | ||
| CN104711240B (zh) | 禽呼肠孤病毒σA蛋白及其相关生物材料的应用 | |
| CN105879060B (zh) | 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗 | |
| Alharbi et al. | Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity | |
| CN113423724B (zh) | Ebv表位高亲和力t细胞受体 | |
| EP3159411A1 (en) | Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof |